Undersøgelse af INBRX-106 og INBRX-106 i kombination med Pembrolizumab hos forsøgspersoner med lokalt avancerede eller metastatiske solide tumorer (hexavalent OX40-agonist)
En åben-label, multicenter, første-i-menneske, dosis-eskalering, fase 1-undersøgelse af INBRX-106 og INBRX-106 i kombination med Pembrolizumab i forsøgspersoner med lokalt avancerede eller metastatiske solide tumorer
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
- Medicin: INBRX-106 - Hexavalent OX40 agonist antibody
- Medicin: pembrolizumab 200 mg
- Medicin: pembrolizumab 400 mg
- Medicin: Carboplatin AUC-5
- Medicin: Pemetrexed 500 mg/m2
- Medicin: Cisplatin 75mg/m2
- Medicin: Carboplatin AUC-6
- Medicin: Paclitaxel 200mg/m2
- Medicin: Nab paclitaxel 100mg/m2
- Medicin: Gemcitabine (1000 mg/m2)
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Study Director - Inhibrx Biosciences, Inc
- Telefonnummer: 858-500-7833
- E-mail: clinicaltrials@inhibrx.com
Studiesteder
-
-
California
-
Duarte, California, Forenede Stater, 91010
- Aktiv, ikke rekrutterende
- City of Hope
-
Glendale, California, Forenede Stater, 91204
- Rekruttering
- Oncura Health
-
Kontakt:
- Elizabeth Brown
- E-mail: Elizabeth.Brown@lahomg.com
-
Ledende efterforsker:
- Sungwon Kyung, MD
-
La Jolla, California, Forenede Stater, 92037
- Ikke rekrutterer endnu
- UC San Diego Health - Moores Cancer Center
-
Ledende efterforsker:
- Lyudmila Bazhenova, MD
-
Los Angeles, California, Forenede Stater, 90027
- Rekruttering
- California Research Institute
-
Ledende efterforsker:
- Ghassan Al-Jazayrly, MD
-
Kontakt:
- Swati Shrestha
- E-mail: sw@caresinst.com
-
Los Angeles, California, Forenede Stater, 90069
- Rekruttering
- Valkyrie Clinical Trials
-
Ledende efterforsker:
- David Berz, MD
-
Kontakt:
- Myo Zaw
- E-mail: myo.zaw@valkyrieclinicaltrials.com
-
Los Angeles, California, Forenede Stater, 90033
- Ikke rekrutterer endnu
- University of Southern California Norris Comprehensive Cancer Center
-
Ledende efterforsker:
- Jorge Nieva, MD
-
Murrieta, California, Forenede Stater, 92562
- Rekruttering
- Valkyrie Clinical Trials
-
Ledende efterforsker:
- David Berz, MD
-
Kontakt:
- Isabella Gudino
- E-mail: Isabella.gudino@vctcare.com
-
Santa Rosa, California, Forenede Stater, 95403
- Rekruttering
- Providence Medical Foundation
-
Ledende efterforsker:
- Ian Anderson, MD
-
Kontakt:
- Clinical Research Coordinator
- Telefonnummer: 1181 707-521-3810
- E-mail: jackson.barnard@providence.org
-
-
Colorado
-
Lakewood, Colorado, Forenede Stater, 80228
- Ikke rekrutterer endnu
- Valkyrie Clinical Trials - Colorado
-
Ledende efterforsker:
- Jason Henry, MD
-
-
Florida
-
Clermont, Florida, Forenede Stater, 34711
- Rekruttering
- Clermont Oncology Center
-
Ledende efterforsker:
- Gopal Kunta, MD
-
Kontakt:
- Kiran Penta
- E-mail: kiran@aorcorp.com
-
Orange City, Florida, Forenede Stater, 32763
- Rekruttering
- Mid Florida Hematology and Oncology Center
-
Ledende efterforsker:
- Santosh Nair, MD
-
Kontakt:
- Kiran Penta
- E-mail: kiran@aorcorp.com
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Aktiv, ikke rekrutterende
- Winship Cancer Institute - Emory University
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Ikke rekrutterer endnu
- University of Illinois Cancer Center
-
Ledende efterforsker:
- Frank Weinberg, MD, PhD
-
Chicago, Illinois, Forenede Stater, 60637
- Aktiv, ikke rekrutterende
- The University of Chicago Medical Center
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa
-
Ledende efterforsker:
- Douglas Laux, MD
-
Kontakt:
- Jordan Harrelson
- Telefonnummer: 319-467-5831
- E-mail: Jordan-harrelson@uiowa.edu
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- Rekruttering
- Norton Cancer Institute
-
Ledende efterforsker:
- John Hamm, MD
-
Kontakt:
- Jenn Broadway, RN
- Telefonnummer: 19535 502-629-2500
- E-mail: Jennifer.Broadway@nortonhealthcare.org
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Rekruttering
- Henry Ford Cancer Institute
-
Ledende efterforsker:
- Amy Weise, MD
-
Kontakt:
- Mahmoud Hossami
- Telefonnummer: 313-725-7842
- E-mail: mhossam1@hfhs.org
-
Detroit, Michigan, Forenede Stater, 48201
- Afsluttet
- Barbara Ann Karmanos Cancer Institute
-
Grand Rapids, Michigan, Forenede Stater, 49546
- Aktiv, ikke rekrutterende
- START Midwest
-
-
Minnesota
-
Saint Louis Park, Minnesota, Forenede Stater, 55426
- Aktiv, ikke rekrutterende
- HealthPartners Cancer Research Center
-
Saint Paul, Minnesota, Forenede Stater, 55101
- Afsluttet
- HealthPartners Cancer Research Center (Regions Hospital)
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Ikke rekrutterer endnu
- Washington University in St. Louis School of Medicine
-
Ledende efterforsker:
- Brett Herzog, MD, PhD
-
-
Montana
-
Billings, Montana, Forenede Stater, 59102
- Afsluttet
- Intermountain Health Cancer Centers of Montana
-
-
Nebraska
-
Grand Island, Nebraska, Forenede Stater, 68803
- Ikke rekrutterer endnu
- Nebraska Cancer Specialists - Grand Island
-
Ledende efterforsker:
- Ralph Hauke, MD
-
Omaha, Nebraska, Forenede Stater, 68130
- Rekruttering
- Nebraska Cancer Specialists
-
Ledende efterforsker:
- Ralph Hauke, MD
-
Kontakt:
- Lindsey Becker
- Telefonnummer: 402-691-5255
- E-mail: lbecker@nebraskacancer.com
-
-
New Jersey
-
Camden, New Jersey, Forenede Stater, 08103
- Ikke rekrutterer endnu
- MD Anderson Cancer Center at Cooper
-
Ledende efterforsker:
- Polina Khrizman, MD
-
-
New York
-
The Bronx, New York, Forenede Stater, 10467
- Aktiv, ikke rekrutterende
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Aktiv, ikke rekrutterende
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97213
- Aktiv, ikke rekrutterende
- Providence Portland Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater, 18103
- Ikke rekrutterer endnu
- Lehigh Valley Health Network
-
Ledende efterforsker:
- Muhammad Rizvi, MD
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37923
- Ikke rekrutterer endnu
- University of Tennessee Health Science Center
-
Ledende efterforsker:
- Sean Jordan, MD
-
Nashville, Tennessee, Forenede Stater, 37204
- Aktiv, ikke rekrutterende
- Vanderbilt University School of Medicine
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75230
- Afsluttet
- Sarah Cannon Research Institute at Mary Crowley
-
El Paso, Texas, Forenede Stater, 79915
- Afsluttet
- Renovatio Clinical - El Paso
-
San Antonio, Texas, Forenede Stater, 78229
- Afsluttet
- NEXT Oncology
-
The Woodlands, Texas, Forenede Stater, 77380
- Afsluttet
- Renovatio Clinical
-
Tyler, Texas, Forenede Stater, 75701
- Rekruttering
- The University of Texas Health Science Center at Tyler
-
Kontakt:
- Chaney Story
- E-mail: Chaney.Story@uttyler.edu
-
Ledende efterforsker:
- Erminia Massarelli, MD, PhD, MS
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Afsluttet
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Froedtert Hospital and the Medical College of Wisconsin
-
Ledende efterforsker:
- Jonathan Thompson, MD
-
Kontakt:
- Ellen Smith
- E-mail: eksmith@mcw.edu
-
-
-
-
-
Singapore, Singapore
- Afsluttet
- Curie Oncology
-
Singapore, Singapore
- Afsluttet
- Icon Cancer Centre Farrer Park
-
Singapore, Singapore
- Afsluttet
- Icon Cancer Centre Mount Alvernia
-
-
-
-
-
Busan, Sydkorea
- Ikke rekrutterer endnu
- Inje University College of Medicine
-
Ledende efterforsker:
- IL-Hwan Kim, MD, PhD
-
Cheongju-si, Sydkorea
- Ikke rekrutterer endnu
- Chungbuk National University Hospital
-
Ledende efterforsker:
- Ki-Hyeong Lee, MD
-
Gyeonggi-do, Sydkorea
- Rekruttering
- The Catholic University of Korea, St. Vincent's Hospital
-
Ledende efterforsker:
- Byoung Yong Shim
-
Hwasun, Sydkorea
- Ikke rekrutterer endnu
- Chonnam National University Hwasun Hospital
-
Ledende efterforsker:
- In-Jae Oh, MD, MS, PhD
-
Incheon, Sydkorea
- Ikke rekrutterer endnu
- Gachon University Gil Medical Center
-
Ledende efterforsker:
- Eun Kyung Cho, PhD, M.S
-
Seongnam-si, Sydkorea
- Ikke rekrutterer endnu
- CHA Bundang Medical Center
-
Ledende efterforsker:
- Yoon Beom Sang
-
Seoul, Sydkorea
- Rekruttering
- Asan Medical Center
-
Kontakt:
- Bokyeong Jung, RN
- E-mail: bokyeong_jung@amc.seoul.kr
-
Ledende efterforsker:
- Dae Ho Lee, MD
-
Seoul, Sydkorea
- Rekruttering
- Severance Hospital, Yonsei University Health System
-
Kontakt:
- Miyeon Lee
- E-mail: lee_my@yuhs.ac
-
Ledende efterforsker:
- Sun Mun Lim
-
Seoul, Sydkorea
- Rekruttering
- The Catholic University of Korea Seoul St. Mary's Hospital,
-
Ledende efterforsker:
- SookHee Hong
-
Kontakt:
- Na Ayn
- E-mail: Ahnna331@gmail.com
-
Seoul, Sydkorea
- Ikke rekrutterer endnu
- Korea University Anam Hospital
-
Ledende efterforsker:
- Yoon Ji Choi, MD, MS, PhD
-
Seoul, Sydkorea
- Ikke rekrutterer endnu
- Hanyang University Seoul Hospital
-
Ledende efterforsker:
- Myung- Ju Ahn, MD, PhD, MS
-
Seoul, Sydkorea
- Ikke rekrutterer endnu
- Korea University Guro Hospital
-
Ledende efterforsker:
- Sung Yong Lee
-
Ledende efterforsker:
- Sung Yong Lee, MD, MS, PhD
-
Suwon, Sydkorea
- Ikke rekrutterer endnu
- Ajou University Hospital
-
Ledende efterforsker:
- Yong-Won Choi, MD
-
-
-
-
-
Changhua, Taiwan
- Aktiv, ikke rekrutterende
- Changhua Christian Hospital (CCH)
-
Kaohsiung City, Taiwan
- Aktiv, ikke rekrutterende
- E-Da Cancer Hospital
-
Kaohsiung City, Taiwan
- Aktiv, ikke rekrutterende
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
Tainan, Taiwan
- Aktiv, ikke rekrutterende
- National Cheng Kung University Hospital
-
Taipei, Taiwan
- Afsluttet
- Taipei Veterans General Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Select Inclusion Criteria:
- Males or females aged ≥18 years.
- Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
- Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
- Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
- For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
- For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
- For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
- All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
- PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
- Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.
Select Exclusion Criteria:
- Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
- Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
- Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
- Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
- Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
- Major surgery within 4 weeks prior to enrollment on this trial.
- Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
- Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- Additional in- and exclusion criteria per protocol.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part 1 INBRX-106 Escalation (Not Recruiting)
INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Eksperimentel: Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)
INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
|
|
Eksperimentel: Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
|
|
Eksperimentel: Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)
Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
|
|
Eksperimentel: Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Andre navne:
|
|
Eksperimentel: Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Andre navne:
|
|
Aktiv komparator: Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Eksperimentel: Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)
Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Eksperimentel: Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
|
|
Eksperimentel: Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting
Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
|
|
Eksperimentel: Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)
Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Andre navne:
|
|
Eksperimentel: Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Andre navne:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 |
|
Eksperimentel: Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4 |
|
Eksperimentel: Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
|
|
Eksperimentel: Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC
Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Andre navne:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Andre navne:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4 |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Tidsramme: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Tidsramme: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
Tidsramme: ~2 years
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab |
~2 years
|
|
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
Tidsramme: ~2 years
|
The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1 |
~2 years
|
|
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
Tidsramme: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
Tidsramme: ~2 years
|
Major pathological response (mPR) and pathological complete response (cPR) criteria. |
~2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area under the serum concentration time curve (AUC) of INBRX-106
Tidsramme: ~2 years
|
Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Maximum observed serum concentration (Cmax) of INBRX-106
Tidsramme: ~2 years
|
Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Trough observed serum concentration (Ctrough) of INBRX-106
Tidsramme: ~2 years
|
Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Time to Cmax (Tmax) of INBRX-106
Tidsramme: ~2 years
|
Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Immunogenicity of INBRX-106
Tidsramme: ~2 years
|
Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Tidsramme: ~2 years
|
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). |
~2 years
|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Tidsramme: ~2 years
|
Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
~2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Studieleder: Clinical Lead, Inhibrx Biosciences, Inc
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- Hoved- og halskræft
- Lungekræft
- NSCLC
- Ikke-småcellet lungekræft
- Karcinom
- Neoplasmer
- Immunterapi
- Pembrolizumab
- Kemoterapi
- Keytruda
- HNSCC
- Neoadjuvans
- Antineoplastiske midler
- Adjuvans
- Faste tumorer
- Mundkræft
- Orofaryngeal cancer
- INBRX-106
- Antineoplastiske midler, immunologiske
- Neoplasmer i hoved og hals
- Neoplasmer, kirtel og epitel
- Neoplasmer efter histologisk type
- Neoplasmer efter sted
- Planocellulært karcinom i hoved og hals
- Molekylære mekanismer for farmakologisk virkning
- PD-L1 positiv
- Neoplasmer, pladecelle
- Karcinom, pladecelle
- Hypopharynx kræft
- Fase 1 og Fase 2
- Fase 1 og fase 2 kliniske forsøg
- OX40-receptoragonist
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Mundsygdomme
- Stomatognatiske sygdomme
- Urogenitale neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Luftvejssygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Lungesygdomme
- Adenocarcinom
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Hudsygdomme
- Urologiske neoplasmer
- Otorhinolaryngologiske sygdomme
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Nyre-neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Neuroendokrine tumorer
- Pharyngeale neoplasmer
- Otorhinolaryngologiske neoplasmer
- Pharyngeale sygdomme
- Nevi og melanomer
- Neoplasmer i huden
- Hud- og bindevævssygdomme
- Planocellulært karcinom i hoved og hals
- Neoplasmer
- Neoplasmer i maven
- Karcinom
- Lungeneoplasmer
- Karcinom, pladecelle
- Karcinom, nyrecelle
- Karcinom, ikke-småcellet lunge
- Neoplasmer i hoved og hals
- Melanom
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Neoplasmer, pladecelle
- Mundens neoplasmer
- Carcinom, overgangscelle
- Orofaryngeale neoplasmer
- Neoplasmer efter sted
- Hypopharyngeale neoplasmer
- Aminosyrer, peptider og proteiner
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Uorganiske kemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Guanine
- Hypoxanthines
- Purinoner
- Puriner
- Glutamater
- Aminosyrer, sur
- Aminosyrer
- Aminosyrer, dicarboxylic
- Taxoider
- Cyclodecanes
- Diterpenes
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Sundhedsøkonomi og organisationer
- Platinforbindelser
- Økonomi
- Pemetrexed
- Gemcitabin
- Paclitaxel
- Cisplatin
- pembrolizumab
- Skatter
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- Ph 1 Ph 2 INBRX-106
- KEYNOTE A99 and MK-3475-A99 (Anden identifikator: Merck Sharp & Dohme LLC)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .